News >

Distinguishing Between Frontline Monotherapies and Combos in mRCC

Caroline Seymour
Published: Monday, Aug 12, 2019

Richard W. Joseph, MD

Richard W. Joseph, MD

Risk status is now not only a prognostic factor, but the main predictive factor when it comes to guiding treatment selection for patients with newly diagnosed metastatic renal cell carcinoma (mRCC), said Richard W. Joseph, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication